Results 11 to 20 of about 1,006,148 (403)

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

New England Journal of Medicine, 2020
BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman, Jacqueline S. Garcia, A. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, Jianxiang Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R. Lemoli, Kazuhito Yamamoto, S. Yoon, J. Jang, S. Yeh, M. Turgut, W. Hong, Ying Zhou, J. Potluri, K. Pratz   +29 more
semanticscholar   +1 more source

Acute myeloid leukemia: current progress and future directions

Blood Cancer Journal, 2021
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian, T. Kadia, C. Dinardo, N. Daver, G. Borthakur, E. Jabbour, G. Garcia-Manero, M. Konopleva, F. Ravandi   +8 more
semanticscholar   +1 more source

Advances in acute myeloid leukemia

British medical journal, 2021
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar   +1 more source

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Leukemia, 2020
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus, M. Baccarani, R. Silver, C. Schiffer, J. Apperley, F. Cervantes, R. Clark, J. Cortes, M. Deininger, F. Guilhot, H. Hjorth-Hansen, T. Hughes, J. Janssen, H. Kantarjian, Dong-Kee Kim, R. Larson, J. Lipton, F. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, J. Radich, D. Réa, J. Richter, G. Rosti, P. Rousselot, G. Saglio, Susanne Saussele, S. Soverini, J. Steegmann, A. Turkina, A. Zaritskey, Ruediger Hehlmann   +33 more
semanticscholar   +1 more source

Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]

Einstein (São Paulo), 2011
Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman, Fabio Pires de Souza Santos, Belinda Simões, Elias Hallack Atta, Fernando Callera, Jane de Almeida Dobbin, Éderson Roberto Mattos, Angelo Atalla, Angelo Maiolino, Maria Aparecida Zanichelli, Cristiane Fração Diefenbach, Marcia Torresan Delamain, Nelson Hamerschlak   +12 more
doaj   +3 more sources

CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]

, 2008
The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi, Akashi, Bai, Bottazzi, Bruserud, Cheng, Christensen, Conkright, Crans-Vargas, Deepa B. Shankar, Dejah R. Judelson, Desdouets, Deshpande, Elliot M. Landaw, Fried, Fu, Hestdal, Impey, Ingrid Schmid, Jamieson, Jenny Chang, Jerry C. Cheng, Kathleen M. Sakamoto, Kentaro Kinjo, Kim, Kinjo, Kohn, Kondo, Koschmieder, Koya, Krishan, Kwon, Lee, Mayr, Mendoza, Miyoshi, Montminy, Ninomiya, Noriyuki Kasahara, Passegué, Ravi Bhatia, Rehemtulla, Renata Stripecke, Scherr, Shah, Shankar, Shankar, Shaywitz, Stripecke, Traver, Tuschl, Van Etten, Ventura, Winston S. Wu, Wong, Yuan   +55 more
core   +3 more sources

Acute Myeloid Leukemia

Apollo Medicine, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone, Margaret R, O'Donnell, Mikkael A, Sekeres   +2 more
openaire   +3 more sources

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Biomarkers of leukemia risk: benzene as a model. [PDF]

, 1998
Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core   +3 more sources

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.

The Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding ...
D. Pollyea, D. Bixby, A. Perl, V. Bhatt, J. Altman, F. Appelbaum, M. de Lima, A. Fathi, J. Foran, I. Gojo, Aric Hall, Meagan A. Jacoby, J. Lancet, G. Mannis, G. Marcucci, Mike G Martin, A. Mims, Jadee L. Neff, R. Nejati, R. Olin, M. Percival, T. Prebet, Amanda C. Przespolewski, D. Rao, F. Ravandi-Kashani, P. Shami, R. Stone, S. Strickland, K. Sweet, P. Vachhani, M. Wieduwilt, K. Gregory, Ndiya Ogba, M. Tallman   +33 more
semanticscholar   +1 more source